Bio-Techne (NASDAQ: TECH) financial statements
The consolidated income statement, balance sheet and cash flow statement of Bio-Techne for its last 10 fiscal years, as filed with the regulator, in millions of US dollars. At the end of fiscal 2026 it had $2,587m in total assets and $2,108m in equity.
Income statement
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1,215m | $1,220m | $1,159m | $1,137m | $1,106m | $931.0m | $738.7m | $714.0m | $643.0m | $563.0m |
| Cost of sales | $416.0m | $429.4m | $389.3m | $366.9m | $349.1m | $298.2m | $255.5m | $240.5m | $210.9m | $188.5m |
| Gross profit | $799.1m | $790.3m | $769.7m | $769.8m | $756.5m | $632.9m | $483.2m | $473.5m | $432.1m | $374.5m |
| Operating profit | $251.9m | $102.3m | $206.7m | $298.9m | $296.6m | $237.3m | $157.4m | $146.7m | $136.2m | $120.6m |
| Finance costs | $9.6m | $8.5m | $15.7m | $11.2m | $11.3m | $14.0m | $19.2m | $21.7m | $10.2m | $7.4m |
| Profit before tax | $240.7m | $98.5m | $185.7m | $338.7m | $301.4m | $148.2m | $276.5m | $112.0m | $126.0m | $112.0m |
| Income tax | $58.8m | $25.1m | $17.6m | $53.2m | $38.3m | $8.6m | $47.2m | $15.9m | $0.2m | $35.9m |
| Net profit | $181.9m | $73.4m | $168.1m | $285.3m | $272.1m | $140.4m | $229.3m | $96.1m | $126.2m | $76.1m |
| Earnings per share | $1.17 | $0.47 | $1.07 | $1.81 | $6.93 | $3.62 | $6.00 | $2.54 | $3.36 | $2.04 |
| Diluted earnings per share | $1.16 | $0.46 | $1.05 | $1.76 | $6.63 | $3.47 | $5.82 | $2.47 | $3.31 | $2.03 |
| Depreciation and amortisation | $97.4m | $109.9m | $111.7m | $107.2m | $101.1m | $87.7m | $82.7m | $78.2m | $64.5m | $60.0m |
Balance sheet
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $2,587m | $2,558m | $2,704m | $2,639m | $2,295m | $2,263m | $2,028m | $1,884m | $1,593m | $1,558m |
| Current assets | $744.4m | $608.3m | $617.4m | $621.5m | $605.6m | $510.6m | $520.9m | $412.6m | $398.4m | $348.0m |
| Inventories | $195.7m | $189.4m | $179.7m | $171.6m | $141.1m | $116.7m | $103.2m | $91.1m | $85.6m | $60.2m |
| Property, plant and equipment | $231.8m | $245.7m | $251.2m | $226.2m | $223.2m | $207.9m | $176.8m | $154.0m | $145.3m | $135.1m |
| Goodwill | $975.4m | $980.9m | $972.7m | $872.7m | $822.1m | $843.1m | $728.3m | $732.7m | $597.9m | $579.0m |
| Cash | $264.7m | $162.2m | $151.8m | $180.6m | $172.6m | $199.1m | $146.6m | $100.9m | $122.0m | $91.6m |
| Current liabilities | $163.7m | $175.8m | $159.4m | $128.5m | $176.0m | $152.3m | $106.7m | $102.0m | $79.5m | $135.5m |
| Equity | $2,108m | $1,919m | $2,069m | $1,967m | $1,702m | $1,563m | $1,381m | $1,166m | $1,079m | $949.6m |
| Equity including minorities | $2,108m | $1,919m | $2,069m | $1,967m | $1,701m | $1,571m | $1,381m | $1,166m | $1,079m | $949.6m |
| Minority interests | — | $0.0m | $0.0m | $0.0m | −$0.8m | $8.3m | $0.0m | $0.0m | $0.0m | — |
Cash flow statement
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $292.1m | $287.6m | $299.0m | $254.4m | $325.3m | $352.2m | $205.2m | $181.6m | $170.4m | $143.7m |
| Investing cash flow | −$18.2m | −$35.2m | −$203.0m | −$265.6m | −$96.9m | −$243.5m | $27.1m | −$336.8m | −$38.7m | −$306.0m |
| Financing cash flow | −$169.1m | −$253.9m | −$122.4m | $22.6m | −$242.9m | −$62.6m | −$183.8m | $134.4m | −$99.2m | $189.1m |
| Capital expenditure | −$28.9m | −$31.0m | −$62.9m | −$38.2m | −$44.9m | −$44.3m | −$51.7m | −$25.4m | −$20.9m | −$15.2m |
| Dividends paid | −$49.9m | −$50.4m | −$50.4m | −$50.3m | −$50.2m | −$49.6m | −$48.9m | −$48.4m | −$48.0m | −$47.3m |
Where each figure comes from
From the annual report (Form 10-K) that Bio-Techne files with the SEC. The filing for each fiscal year: 2026 · 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017. If an item is not tagged in the filing, it is not in the table. The summary of the last fiscal year is on the Bio-Techne page.
Dividend per share of Bio-Techne by fiscal year, with the filing behind every figure: Bio-Techne dividend history.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.